NEWS RELEASE

Teijin Pharma Grants Global Exclusive License to Bioprojet
to Develop a New Orexin Receptor 2 Agonist Investigational
Candidate for Narcolepsy
Tokyo, Japan, April 10, 2024 --- Teijin Pharma Limited, the core company of the TeijinGroup’s healthcare business, announced today that it has entered into an exclusive
global licensing agreement with Bioprojet, a French pharmaceutical company. Under theterms of the agreement, Teijin Pharma grants Bioprojet exclusive worldwide rights toresearch, develop, manufacture and commercialize an investigational candidate fornarcolepsy.
The investigational candidate is a highly potent and selective orexin 2 receptor agonist
discovered at the Teijin Institute for Bio-medical Research in Tokyo. The candidate is
expected to compensate for a deficiency in orexins, brain peptides that help sustain
alertness and prevent rapid eye movement (REM) sleep from occurring at the wrong
times. The mechanism of action (MoA) of this class of compounds has been
demonstrated and could represent the next novel MoA for the treatment of narcolepsy
and other sleep/wake disorders.
Narcolepsy is a sleep disorder that is characterized by excessive daytime sleepinessand cataplexy (episodic loss of muscle tone triggered by emotions). Its prevalence isestimated to be around 25 to 50 cases per 100,000 people. Current approved therapies
objectives are to promote wakefulness and decrease cataplexy attacks.
Bioprojet, founded in 1982, researches, develops and sells pharmaceuticals in areas
such as neurology, immunology, allergies and rare diseases. The company’s leading
product is pitolisant (brand name: WakixⓇ), a histamine H3 receptor antagonist/inverseagonist that is already widely marketed for the treatment of both excessive daytime
sleepiness and cataplexy in patients with narcolepsy.
According to the terms of the agreement, Teijin Pharma will receive an upfront paymentof $30 million USD from Bioprojet. In addition, it is eligible to receive approximately $400
million USD in total milestone revenue according to the progress of development and theachievement of sales targets, as well as tiered annual net sales royalties.
Teijin Pharma has made this agreement to contribute to improving the quality of life（QOL）
for narcolepsy patients around the world by licensing this compound to Bioprojet, which
has a proven track record in developing and commercializing pitolisant for the treatmentof narcolepsy.

Teijin Group’s healthcare business has been transforming its business model to support patientswith rare diseases based on the infrastructure in home healthcare business. In the discovery
section of pharmaceutical business, through licensing or external partnerships, Teijin willcontinue making a social contribution by delivering innovative treatments to patients around theworld.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: highperformance materials and healthcare solutions. Established in 1918 as Japan’s firstrayon manufacturer, Teijin today comprises some 170 companies employing 20,000
people in 20 countries. Through “Human Chemistry, Human Solutions,” Teijin relentlessly
strives to aims to be a company that supports the society of the future by protecting theglobal environment and addressing the needs of people and communities. Teijin posted
consolidated sales of JPY 1,018.8 billion (USD 7.6 billion) and total assets of JPY 1,242.4
billion (USD 9.2 billion) in the fiscal year ending March 31, 2023.
Press Contact
Corporate Communication Department
Teijin Limited
pr@teijin.co.jp